184 related articles for article (PubMed ID: 25671235)
1. Targeted radionuclides for prostate cancer bone metastases.
Ito T; Bilusic M; Chen D
Urol Oncol; 2015 Jan; 33(1):2-6. PubMed ID: 25671235
[No Abstract] [Full Text] [Related]
2. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
4. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
5. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
Mortensen J; Højgaard L
Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
[TBL] [Abstract][Full Text] [Related]
6. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
7. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
Shore ND
Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
[No Abstract] [Full Text] [Related]
8. Re: Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Taneja SS
J Urol; 2015 Mar; 193(3):847-8. PubMed ID: 25765385
[No Abstract] [Full Text] [Related]
9. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
10. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Dorff TB; Gross ME
Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer - Therapy with radium-223.
Brito AE; Amorim BJ; Martello M; Bernardo WM; Etchebehere E;
Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1019-1023. PubMed ID: 29489974
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
13. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Morgan SC
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
[TBL] [Abstract][Full Text] [Related]
15. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
Yoshida K; Kaneta T; Takano S; Sugiura M; Kawano T; Hino A; Yamamoto T; Shizukuishi K; Kaneko M; Zurth C; Inoue T
Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279
[TBL] [Abstract][Full Text] [Related]
17. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; O'Bryan-Tear CG; Thuresson M; Bolstad B; Bruland ØS
Clin Genitourin Cancer; 2013 Mar; 11(1):20-6. PubMed ID: 23021204
[TBL] [Abstract][Full Text] [Related]
18. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
19. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Ram P; Mandal S; K Das M; Nayak P
Prostate; 2023 May; 83(6):613. PubMed ID: 36717109
[No Abstract] [Full Text] [Related]
20. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
Nilsson S
Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
